Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 39,800 shares of Opko Health stock in a transaction dated Tuesday, July 25th. The stock was purchased at an average price of $6.41 per share, with a total value of $255,118.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $19,671,975.91. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, July 24th, Phillip Md Et Al Frost purchased 45,000 shares of Opko Health stock. The stock was acquired at an average cost of $6.42 per share, for a total transaction of $288,900.00.
  • On Thursday, July 20th, Phillip Md Et Al Frost purchased 5,400 shares of Opko Health stock. The stock was acquired at an average cost of $6.46 per share, for a total transaction of $34,884.00.
  • On Monday, July 17th, Phillip Md Et Al Frost purchased 1,800 shares of Opko Health stock. The stock was acquired at an average cost of $6.04 per share, for a total transaction of $10,872.00.
  • On Friday, July 14th, Phillip Md Et Al Frost purchased 12,600 shares of Opko Health stock. The stock was acquired at an average cost of $6.16 per share, for a total transaction of $77,616.00.
  • On Wednesday, July 12th, Phillip Md Et Al Frost purchased 3,600 shares of Opko Health stock. The stock was acquired at an average cost of $6.12 per share, for a total transaction of $22,032.00.
  • On Monday, July 10th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The stock was purchased at an average cost of $6.19 per share, for a total transaction of $309,500.00.
  • On Thursday, July 6th, Phillip Md Et Al Frost bought 25,000 shares of Opko Health stock. The stock was purchased at an average cost of $6.29 per share, for a total transaction of $157,250.00.
  • On Monday, July 3rd, Phillip Md Et Al Frost bought 60,800 shares of Opko Health stock. The stock was purchased at an average cost of $6.44 per share, for a total transaction of $391,552.00.
  • On Friday, June 30th, Phillip Md Et Al Frost purchased 3,600 shares of Opko Health stock. The shares were bought at an average price of $6.58 per share, for a total transaction of $23,688.00.
  • On Wednesday, June 28th, Phillip Md Et Al Frost purchased 1,800 shares of Opko Health stock. The shares were bought at an average price of $6.87 per share, for a total transaction of $12,366.00.

Opko Health, Inc. (NASDAQ OPK) traded down 0.6969% during mid-day trading on Wednesday, reaching $6.3554. The company had a trading volume of 376,840 shares. Opko Health, Inc. has a one year low of $5.99 and a one year high of $12.15. The firm’s market capitalization is $3.56 billion. The firm’s 50-day moving average is $6.48 and its 200-day moving average is $7.52.

Opko Health (NASDAQ:OPK) last issued its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by $0.02. Opko Health had a negative net margin of 3.60% and a negative return on equity of 2.13%. The business had revenue of $296.10 million during the quarter, compared to analyst estimates of $313.36 million. During the same period last year, the firm posted ($0.02) earnings per share. Opko Health’s quarterly revenue was up 1.8% compared to the same quarter last year. On average, equities research analysts anticipate that Opko Health, Inc. will post ($0.20) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/07/26/phillip-md-et-al-frost-acquires-39800-shares-of-opko-health-inc-nasdaqopk-stock.html.

Several institutional investors have recently modified their holdings of OPK. BlackRock Inc. increased its stake in shares of Opko Health by 11,481.3% in the first quarter. BlackRock Inc. now owns 22,645,285 shares of the biotechnology company’s stock valued at $181,163,000 after buying an additional 22,449,752 shares during the period. Norges Bank bought a new stake in shares of Opko Health during the fourth quarter valued at about $30,421,000. State Street Corp increased its stake in shares of Opko Health by 40.3% in the first quarter. State Street Corp now owns 10,926,560 shares of the biotechnology company’s stock valued at $87,412,000 after buying an additional 3,138,685 shares during the period. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management increased its stake in shares of Opko Health by 62.4% in the first quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management now owns 5,061,154 shares of the biotechnology company’s stock valued at $40,489,000 after buying an additional 1,944,549 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Opko Health by 4.4% in the first quarter. Vanguard Group Inc. now owns 26,322,001 shares of the biotechnology company’s stock valued at $210,576,000 after buying an additional 1,112,843 shares during the period. 23.64% of the stock is currently owned by institutional investors.

Several research analysts recently issued reports on the stock. Jefferies Group LLC reiterated a “hold” rating and set a $8.00 price target on shares of Opko Health in a research report on Monday, June 12th. Zacks Investment Research upgraded shares of Opko Health from a “hold” rating to a “buy” rating and set a $7.25 price target on the stock in a research report on Friday, July 21st. Barrington Research upped their price target on shares of Opko Health to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 18th. BidaskClub upgraded shares of Opko Health from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Finally, Ladenburg Thalmann Financial Services restated a “buy” rating and set a $19.50 target price on shares of Opko Health in a research report on Tuesday, June 6th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $14.72.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.